Skip to content
Operation Infinite Justice – Lifestyle
Author:
Telix Pharmaceuticals Limited
Telix and United Imaging Announce Strategic Theranostics Collaboration
June 2, 2026
ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
June 1, 2026
Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences
May 27, 2026
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
May 18, 2026
New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC
May 4, 2026
TLX101-Px (Pixlumi®) MAA Accepted in Europe
April 30, 2026
OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
April 29, 2026
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
April 27, 2026
ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
April 21, 2026
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
April 14, 2026
1
2
Next Page
→